TY - JOUR
T1 - The Limitless Future of RNA Therapeutics
AU - Damase, Tulsi Ram
AU - Sukhovershin, Roman
AU - Boada, Christian
AU - Taraballi, Francesca
AU - Pettigrew, Roderic I.
AU - Cooke, John P.
N1 - Copyright © 2021 Damase, Sukhovershin, Boada, Taraballi, Pettigrew and Cooke.
PY - 2021/3/18
Y1 - 2021/3/18
N2 - Recent advances in the generation, purification and cellular delivery of RNA have enabled development of RNA-based therapeutics for a broad array of applications. RNA therapeutics comprise a rapidly expanding category of drugs that will change the standard of care for many diseases and actualize personalized medicine. These drugs are cost effective, relatively simple to manufacture, and can target previously undruggable pathways. It is a disruptive therapeutic technology, as small biotech startups, as well as academic groups, can rapidly develop new and personalized RNA constructs. In this review we discuss general concepts of different classes of RNA-based therapeutics, including antisense oligonucleotides, aptamers, small interfering RNAs, microRNAs, and messenger RNA. Furthermore, we provide an overview of the RNA-based therapies that are currently being evaluated in clinical trials or have already received regulatory approval. The challenges and advantages associated with use of RNA-based drugs are also discussed along with various approaches for RNA delivery. In addition, we introduce a new concept of hospital-based RNA therapeutics and share our experience with establishing such a platform at Houston Methodist Hospital.
AB - Recent advances in the generation, purification and cellular delivery of RNA have enabled development of RNA-based therapeutics for a broad array of applications. RNA therapeutics comprise a rapidly expanding category of drugs that will change the standard of care for many diseases and actualize personalized medicine. These drugs are cost effective, relatively simple to manufacture, and can target previously undruggable pathways. It is a disruptive therapeutic technology, as small biotech startups, as well as academic groups, can rapidly develop new and personalized RNA constructs. In this review we discuss general concepts of different classes of RNA-based therapeutics, including antisense oligonucleotides, aptamers, small interfering RNAs, microRNAs, and messenger RNA. Furthermore, we provide an overview of the RNA-based therapies that are currently being evaluated in clinical trials or have already received regulatory approval. The challenges and advantages associated with use of RNA-based drugs are also discussed along with various approaches for RNA delivery. In addition, we introduce a new concept of hospital-based RNA therapeutics and share our experience with establishing such a platform at Houston Methodist Hospital.
KW - RNA therapeutics
KW - delivery of RNA therapeutics
KW - hospital-based RNA therapeutics
KW - messenger RNAs (mRNAs)
KW - self-amplifying mRNA
UR - http://www.scopus.com/inward/record.url?scp=85103477297&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103477297&partnerID=8YFLogxK
U2 - 10.3389/fbioe.2021.628137
DO - 10.3389/fbioe.2021.628137
M3 - Review article
C2 - 33816449
AN - SCOPUS:85103477297
SN - 2296-4185
VL - 9
JO - Frontiers in Bioengineering and Biotechnology
JF - Frontiers in Bioengineering and Biotechnology
M1 - 628137
ER -